Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVKD Cadrenal Therapeutics	$12.51 +0.2%	$11.80	$6.89 ▼ $22.90	$25.65M	0.93	33,113 shs	11,941 shs
ENLV Enlivex Therapeutics	$1.10 +4.3%	$1.26	$0.81 ▼ $2.10	$25.90M	0.8	258,873 shs	568,065 shs
PLRZ Polyrizon	$1.03 -4.6%	$0.99	$0.55 ▼ $1,200.00	$6.17M	N/A	3.16 million shs	256,646 shs
RVPH Reviva Pharmaceuticals	$0.52 -4.4%	$0.48	$0.30 ▼ $4.28	$35.02M	-0.05	1.71 million shs	1.54 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVKD Cadrenal Therapeutics	0.00%	-1.58%	+8.62%	-15.39%	+69.57%
ENLV Enlivex Therapeutics	0.00%	-42.31%	-6.42%	+7.69%	-14.63%
PLRZ Polyrizon	0.00%	-1.82%	-29.87%	+27.06%	+107,999,900.00%
RVPH Reviva Pharmaceuticals	0.00%	-0.28%	+14.21%	-47.72%	-44.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CVKD Cadrenal Therapeutics	2.3563 of 5 stars	3.5	3.0	0.0	0.0	1.1	1.7	0.6
ENLV Enlivex Therapeutics	3.1645 of 5 stars	3.7	5.0	0.0	0.0	2.3	0.8	0.6
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	2.669 of 5 stars	3.6	1.0	0.0	0.0	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVKD Cadrenal Therapeutics	3.00	Buy	$32.00	155.80% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	813.24% Upside
PLRZ Polyrizon	0.00	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	3.13	Buy	$7.17	1,291.59% Upside

Current Analyst Ratings Breakdown

Latest PLRZ, ENLV, CVKD, and RVPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	RVPH Reviva Pharmaceuticals	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $3.00
8/18/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/18/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
8/15/2025	RVPH Reviva Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/15/2025	RVPH Reviva Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/27/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$4.17 per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	$315.05 per share	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVKD Cadrenal Therapeutics	-$10.65M	-$8.88	N/A	N/A	N/A	N/A	-265.37%	-196.38%	11/6/2025 (Estimated)
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
PLRZ Polyrizon	-$1.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.65	N/A	N/A	N/A	N/A	N/A	-259.17%	11/13/2025 (Estimated)

Latest PLRZ, ENLV, CVKD, and RVPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	RVPH Reviva Pharmaceuticals	-$0.15	-$0.12	+$0.03	-$0.12	N/A	N/A
8/11/2025	Q2 2025	CVKD Cadrenal Therapeutics	-$1.60	-$1.87	-$0.27	-$1.87	N/A	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVKD Cadrenal Therapeutics	N/A	3.55	3.55
ENLV Enlivex Therapeutics	N/A	7.20	7.20
PLRZ Polyrizon	N/A	10.16	10.16
RVPH Reviva Pharmaceuticals	N/A	0.90	0.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVKD Cadrenal Therapeutics	7.92%
ENLV Enlivex Therapeutics	1.02%
PLRZ Polyrizon	N/A
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
CVKD Cadrenal Therapeutics	26.09%
ENLV Enlivex Therapeutics	12.28%
PLRZ Polyrizon	N/A
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVKD Cadrenal Therapeutics	4	2.05 million	1.51 million	Not Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
PLRZ Polyrizon	N/A	5.99 million	N/A	N/A
RVPH Reviva Pharmaceuticals	5	68.00 million	49.52 million	Optionable

PLRZ, ENLV, CVKD, and RVPH Headlines

Recent News About These Companies

What is Zacks Small Cap's Estimate for RVPH FY2025 Earnings?

August 23 at 2:45 AM | americanbankingnews.com

Roth Capital Issues Negative Outlook for RVPH Earnings

August 22 at 2:29 AM | americanbankingnews.com

Reviva Pharmaceuticals (NASDAQ:RVPH) Receives "Buy" Rating from D. Boral Capital

August 20, 2025 | americanbankingnews.com

RVPH: There May Be A Faster Way

August 19, 2025 | finance.yahoo.com

Reviva Pharmaceuticals Advances Schizophrenia Treatment

August 18, 2025 | tipranks.com

Maxim Group Cuts Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $2.00

August 18, 2025 | americanbankingnews.com

Reviva Pharmaceuticals price target lowered to $3 from $7 at Roth Capital

August 18, 2025 | msn.com

Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Upgraded by Wall Street Zen

August 16, 2025 | americanbankingnews.com

Reviva Narrows Loss 23% in Fiscal Q2

August 14, 2025 | aol.comA

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 14, 2025 | globenewswire.com

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.com

June 29, 2025 | investing.com

Reviva Dives on Stock Offering

June 26, 2025 | baystreet.ca

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

June 26, 2025 | globenewswire.com

Reviva Pharmaceuticals stock falls after announcing public offering

June 25, 2025 | za.investing.com

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.comS

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ, ENLV, CVKD, and RVPH Company Descriptions

Cadrenal Therapeutics NASDAQ:CVKD

$12.51 +0.03 (+0.24%)

As of 03:48 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Enlivex Therapeutics NASDAQ:ENLV

$1.10 +0.05 (+4.29%)

As of 03:49 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Polyrizon NASDAQ:PLRZ

$1.03 -0.05 (-4.62%)

As of 03:29 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.52 -0.02 (-4.36%)

As of 03:49 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time